

ACS TQIP MASSIVE TRANSFUSION IN TRAUMA GUIDELINES



ACS
tqip®

TRAUMA
QUALITY
IMPROVEMENT
PROGRAM



AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

100years



COMMITTEE
ON TRAUMA

Released October 2014

Table of Contents

Introduction	3
Development of a Massive Transfusion Protocol: Engagement and Scope	3
Triggers for Initiating Massive Transfusion	4
Blood Product Resuscitation in the Trauma Bay, Operating Room, and Angiography Suite	5
Massive Transfusion in the Intensive Care Unit	6
Operational Aspects of the Transfusion Service/Blood Bank	6
Endpoints of Transfusion	8
Therapeutic Adjuncts in Massive Transfusion	10
Monitoring System Performance in Massive Transfusion	11
Bibliography	13
Expert Panel	15
Disclaimer	16



Introduction

Hemorrhage is the most common cause of death within the first hour of arrival to a trauma center. More than 80 percent of deaths in the operating room (OR) and nearly 50 percent of deaths in the first 24 hours after injury are due to exsanguination and coagulopathy. While only 3 percent of civilian trauma patients will receive a massive transfusion (>10 units red blood cells [RBC] in 24 hours), these patients consume 70 percent of all blood transfused at a trauma center. Because massive transfusions are unplanned and require the processing and delivery of large amounts of blood products rapidly for a sustained period of time, significant preplanning and coordination between the blood bank, the emergency department, the OR, and delivery personnel is required. The development and implementation of massive transfusion protocols (MTPs) have been associated with a reduction in mortality and overall blood product use in trauma centers. The purpose of the following guidelines is to identify the necessary components of an MTP and address key issues involved in developing an MTP for trauma.

Development of a Massive Transfusion Protocol: Engagement and Scope

An MTP should be a written document, accessible to all, and adopted by the center. All staff should be familiar with the procedures. Initial training and subsequent regular drills are recommended to maintain competency. This process is especially important in trauma centers where MTP initiations are rare, for example, smaller centers. The content of MT protocols should be based on the principles of damage control resuscitation. As such, they should provide for ratio-based blood products that are empirically delivered (hemostatic resuscitation) and have a process for the immediate availability of RBC, plasma, and platelets. Protocols should also include standardization of the assessment of coagulopathy and include assessment and treatment of acidosis, hypothermia, and hypocalcemia.

Massive transfusion protocols should be developed by a multidisciplinary committee that includes, at a minimum, representatives from:

- Transfusion service/blood bank
- Emergency department
- Anesthesia
- Trauma service



The massive transfusion protocol should address:

- Triggers for initiating massive transfusion in trauma
- Resuscitation in the trauma bay, including:
 - ▶ MTP product availability
 - ▶ MTP product delivery
 - ▶ MTP blood product transfusion
- Continuing MTP in the OR, angiography suite, and intensive care unit
- Transfusion service processes for delivery of blood products
- Transfusion targets
- The use of adjuncts for massive transfusion patients
- Termination of the MTP
- Performance improvement monitoring

Triggers for Initiating Massive Transfusion

Predicting the need for MT is difficult. Mortality is improved with rapid activation of a massive transfusion protocol, but complications are increased if patients have unnecessary exposure to blood products. Prediction tools for MT in adult trauma patients have been developed for both military and civilian trauma patients with injuries from penetrating or blunt trauma,

respectively, with specificities that range between 80 percent and 90 percent. One well-validated scoring system is the Assessment of Blood Consumption (ABC) score. The ABC score consists of four variables (pulse >120, SBP<90, + FAST, and penetrating torso injury), each assigned one point. A score of two or more warrants MTP activation. The ABC score overestimates the need for transfusion, with a positive predictive value of 50 percent to 55 percent, meaning that 45 percent to 50 percent of patients in whom MTP is activated will not need a massive transfusion. However, the ABC score is excellent at identifying who will not need massive transfusion, with a negative predictive value of less than 5 percent, meaning it identifies more than 95 percent of all patients who will need a massive transfusion. Other prediction scores have been developed and all include the presence of severe tissue injury and hemorrhagic shock as important risk factors.

Criteria to trigger the activation of an MTP should include one or more of the following:

- ABC score of two or more
- Persistent hemodynamic instability
- Active bleeding requiring operation or angioembolization
- Blood transfusion in the trauma bay



Blood Product Resuscitation in the Trauma Bay, Operating Room, and Angiography Suite

Universally compatible RBC (O Rh-negative and O Rh-positive) and thawed plasma should be immediately available and ideally stored in the emergency department (ED). Centers that have used thawed plasma early in resuscitation have seen reductions in blood product utilization and product wastage. In areas where the transfusion service is unable to provide adequate stores of AB plasma, low (anti-B) titer A plasma may be utilized.

For maximum effectiveness, damage control resuscitation (DCR) principles suggest that RBC and plasma should be delivered by a rapid transfuser and through a blood warmer. Initial rate of transfusion should restore perfusion but allow for permissive hypotension until the operation or angioembolization to stop the bleeding has begun. Platelets and cryoprecipitate should not be administered through a blood warmer.

- Universal blood products should be immediately available on patient arrival to support ratio-based transfusion.

If MTP triggers are met:

- Begin universal blood product infusion rather than crystalloid or colloid solutions.

- Transfuse universal RBC and plasma in a ratio between 1:1 and 1:2 (plasma to RBC).
- Transfuse one single donor apheresis or random donor platelet pool for each six units of RBC.
- Blood products should be automatically sent by the transfusion service in established ratios.
- Subsequent coolers should be delivered at 15-minute intervals until the MTP has been terminated.
- The goal is to keep at least one MTP cooler ahead for the duration of the MTP activation.

When the patient is moved from the resuscitation suite to the operating room or the angiography suite it is important that this is communicated to the Transfusion Service so that blood product delivery can continue to the site of patient care. During the procedure rapid delivery and transfusion of products should continue in appropriate ratios and at a rate to keep maintain adequate blood volume while the patient is actively bleeding. Once major bleeding has been controlled and the rate of transfusion has slowed it is appropriate to switch to a laboratory-or point of care (POCT)-based transfusion. For performance improvement purposes the ratio of blood product transfusion should be assessed at the time of bleeding cessation and not necessarily at a specific time point or at the end of an operation or angioembolization.



Massive Transfusion in the Intensive Care Unit

Trauma patients for whom a massive transfusion protocol is activated most frequently require intensive care. Arrival of these patients to the intensive care unit (ICU) marks an important checkpoint, including a systematic review of the patient's prior resuscitative efforts. The ICU accepting team should anticipate arrival of these patients with the necessary equipment to continue rapidly infusing blood products. Attention should be paid to correcting factors that exacerbate coagulopathy, including hypothermia, acidosis, and hypocalcemia. If massive ongoing bleeding persists, the patient may require prompt return to the operating room, particularly if the coagulation status has been normalized.

An appropriate ICU-driven algorithm should be optimized to use blood components for goal-directed therapy.

- Upon arrival in the ICU, baseline laboratory measures should be obtained and then repeated as needed or at least hourly:
 - ▶ INR
 - ▶ aPTT
 - ▶ Fibrinogen level
 - ▶ Hemoglobin or hematocrit
 - ▶ Platelet count
 - ▶ Point-of-care testing/ thromboelastometry and rotational thromboelastography, if available

- ▶ Ionized calcium
- ▶ Blood gas analysis, including base deficit

- Use of empiric fixed ratios of blood products should be followed in the ICU until bleeding is controlled and/or specific laboratory and POCT data are available. These products should be delivered in a ratio between 1:1 and 1:2 (plasma:RBC).
- Once laboratory data are available, resuscitation should be goal directed based on the laboratory findings and clinical evidence of ongoing bleeding.

Operational Aspects of the Transfusion Service/ Blood Bank

A designated trauma center should have an on-site transfusion service that operates 24 hours a day, seven days a week and has specific operating procedures for the rapid early and continued delivery of blood components as dictated by an MTP. The MTP must allow adherence to current, standard safe practices for transfusion. During massive transfusion, timely and precise communication between the trauma team, the ED, the operating room, anesthesia, and the transfusion service regarding availability and need for transfusion products is imperative.

The most efficient way to immediately initiate an MTP is to have a blood refrigerator containing universal donor products in the resuscitation bay. Rapid delivery of subsequent blood coolers from the transfusion service to the resuscitation bay is best accomplished by the assignment of a dedicated runner. A process must be in place to rapidly deliver a group and screen to the transfusion service laboratory to facilitate the availability of crossmatched RBC. Uncrossmatched (O Rh negative or O Rh positive RBC) should be available immediately. Group O Rh negative RBC should be reserved for women of child-bearing potential (younger than 45 to 50 years old). Patients should be switched to crossmatched RBC as soon as it is available, which should be achievable within one hour for most patients (about 97 percent). For a small number of patients who have a positive antibody screen, obtaining crossmatched RBC may take hours. Staffing the transfusion service with technologists trained in antibody investigations is instrumental for providing these patients with compatible RBC. A transfusion medicine specialist should be available to consult with the trauma team regarding compatibility and other issues related to massive transfusion.

Currently RBC can be safely stored for up to six weeks and are released using a first-in, first-out system to minimize wastage. While there is concern that transfusion of RBC with longer storage times in trauma may increase complications, there is no current justification to prioritize the use

of RBC with short storage times to the trauma patient at the expense of other patients. The RECESS and ABLE studies that are underway in the U.S. and Canada may give further guidance in the future.

For an MTP to be effective, universal thawed plasma should be immediately available. This step can be accomplished by storing thawed or liquid (never frozen) plasma. The ideal universal plasma is AB plasma, but unfortunately it is in short supply, as only 4 percent of donors have this blood type. As a result of increased use of AB plasma in resuscitation, shortages of plasma may occur for patients with AB blood type. However, 40 percent of donors are type A and many of them have low titers of anti-B; this low titer plasma can be safely given to almost everyone. In order to avoid overuse or wastage of AB plasma, transfusion services may utilize group A plasma with low anti-B titers. This process requires determining anti-B titer at the time of donation. Patients should be switched to group-specific plasma as soon as the blood group has been determined, which usually takes about 10 minutes. The transfusion service should maintain a sufficient quantity of platelets to support ratio-based massive transfusion. Additional platelets may be needed to support patients with bleeding disorders or those on antiplatelet therapy. Blood products should be transported and stored appropriately. RBC and plasma should be delivered and kept in temperature-controlled coolers. Platelets and cryoprecipitate should not be placed in coolers. Upon termination of MTP, all remaining blood products and coolers should be returned to the transfusion service promptly.



In multicasualty situations, especially when patients are poorly identified, the transfusion service should be notified immediately, and consideration should be given to exclusive use of universal donor blood products until stable identities or aliases can be established.

A designated trauma center or its supporting transfusion service should have on hand and available for immediate release the following:

- ▶ At least eight units of universal donor, uncrossmatched RBC (for example, four units of O Rh negative RBC and four units of O Rh positive RBC)
- ▶ At least eight units of thawed group AB or low titer anti-B group A plasma. Additional plasma should be obtainable from the transfusion service within 15 minutes of MTP activation.
- Uncrossmatched blood products should be delivered until group-matched products are available.
 - ▶ Once the transfusion service has received a blood specimen for group matching, group-matched products should be available within 10 minutes.
 - ▶ Crossmatched RBC should be available within one hour for most patients. Notable rare exceptions include RBC alloantibody, rare blood group, and so on.

- Special consideration for universal product use should be given only in multicasualty situations

Endpoints of Transfusion

To ensure that the MTP protocol does not needlessly waste scarce resources, it is important to determine the criteria and process for termination of the protocol. Based on guidelines for enrollment in the current Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) study, criteria for stopping the MTP should include both anatomic (control of bleeding) and physiologic criteria (normalizing hemodynamic status). The decision to stop should be made by the trauma surgeon in conjunction with the anesthesiologist, if the patient is still in the operating room, or the intensivist/trauma surgeon if in the ICU.

In addition, the exact laboratory value endpoints that should be used to guide further blood product use should be based on published data and the extensive clinical experience of those who are caring for the patient.

- The ratio-driven massive transfusion may be discontinued or downgraded to goal-directed transfusion based on the laboratory findings if surgical bleeding has been controlled by the surgeon in the operating room **OR** there is radiographic and physiologic evidence of bleeding control after angioembolization.



- The MTP should be discontinued when there is recognition that further resuscitation is futile.
- The following should be used as guides to cease therapy with blood and blood components in a patient who is (1) not actively bleeding and (2) still in the acute resuscitation phase:
- RBC transfusions for **hemoglobin** ≥ 10 g/dL
- Plasma transfusion for **prothrombin time (PT)** <18 seconds
- Plasma transfusion for activated **partial thromboplastin time (aPTT)** <35 seconds
- Platelet transfusions for **platelet count** $>150 \times 10^9$
- Cryoprecipitate or fibrinogen concentrate for **fibrinogen level** >180 g/L

If standard thrombelastography (TEG®) is available, the following cut-points for transfusion triggers may also be used:

- Plasma for **r-value** >9 minutes
- Plasma and/or cryoprecipitate (fibrinogen concentrate) for **k-time** >4 minutes
- Cryoprecipitate (or fibrinogen concentrate) and/or plasma for **α -angle** $<60^\circ$
- Platelets for **mA** <55 mm
- Anti-fibrinolytics for **LY30** >7.5 percent

If rapid TEG is available, the following cut-points for transfusion triggers may also be used:

- Plasma for **ACT** >128 seconds
- Plasma and/or cryoprecipitate (fibrinogen concentrate) for **k-time** >2.5 minutes
- Cryoprecipitate (fibrinogen concentrate) and/or plasma for **α -angle** $<60^\circ$
- Platelets for **mA** <55 mm
- Anti-fibrinolytics for **LY30** >3 percent

If rotational thromboelastometry (ROTEM®) is available, the following cut-points for transfusion triggers may also be used:

- Plasma for CT exTEM >100 seconds and/or CT inTEM >230 seconds
- Cryoprecipitate (fibrinogen concentrate) and/or plasma for MCF fibTEM <8 mm
- Platelets for MCF exTEM <45 mm and MCF fibTEM >10 mm
- Anti-fibrinolytics for ML exTEM >15 percent



For the purposes of reporting and documentation in registry and databases, hemorrhage control/hemostasis can be declared when both of the following have been met:

- The surgeon declares hemostasis based on the absence of bleeding requiring intervention in the surgical field **OR** resolution of blush after angioembolization.
- The surgeon and/or anesthesiologists agree that the patient is adequately resuscitated based on the following criteria, if available:
 - Stable or increasing blood pressure, or
 - Stable or decreasing heart rate, or
 - Stable or increasing urine output, or
 - Decreasing requirement for vasopressors to maintain a stable blood pressure

Frequent communication between the members of the resuscitation and surgical teams cannot be overemphasized to guide the resuscitation, plan for continued need for blood products and adjuncts, and determination of when to move toward data-based resuscitation and when to end active resuscitation.

Therapeutic Adjuncts in Massive Transfusion

There are several adjuncts available for massive transfusion. Antifibrinolytic medications, such as tranexemic acid (TXA) or aminocaproic acid, inhibit plasminogen activation and plasmin activity thus stabilizing the clot. Although available and widely used for many years, it was not until the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 (CRASH-2) trial that the use of TXA in trauma was examined. Tranexemic acid has been shown to be effective in a variety of surgical settings, including cardiovascular surgery, orthopaedic surgery, postpartum hemorrhage, and trauma. In trauma, antifibrinolytic agents can be used empirically or in response to findings of increased fibrinolytic activity on POCT.

Recombinant activated factor VIIa was initially developed for the treatment of hemophilia with inhibitors and is only licensed by the U.S. Food and Drug Administration (FDA) for this indication. However, over the last decade, it has been studied and has been used in the setting of traumatic coagulopathy as well as reversal of warfarin-induced anticoagulation in serious bleeding. At this time, the role of factor VIIa is unclear. It certainly appears to reduce transfusion requirement, but lack of long-term mortality benefit and potential increases in morbidity have placed its position in the MTP in doubt.



A variety of prothrombin complex concentrates are currently available. These concentrates contain either three (II, IX and X) or four (II, VII, IX and X) clotting factors. Although widely available in Europe and elsewhere for years, the first FDA-approved four-factor PCC has just been released in the United States. This product is licensed for urgent reversal of warfarin but is sometimes used off-label for management of trauma-induced coagulopathy in Europe.

- TXA 1 gram intravenous over 10 minutes followed by infusion of 1 gram over eight hours is recommended in all injured patients who are actively bleeding and are within three hours of injury.
- PCC is currently only approved for correction of warfarin-induced coagulopathy in bleeding patients. As such, the American College of Chest Physicians Guidelines, 9th Edition, recommends use of PCC over FFP for warfarin reversal in the setting of major bleeding.
- Recombinant VIIa is generally not recommended for management of refractory hemorrhage in trauma.

Monitoring System Performance in Massive Transfusion

Acute hemorrhage associated with traumatic injury places the patient at risk for a myriad of complications. Review of hemorrhage- and transfusion-related complications, along with monitoring of the availability and management of blood products during massive transfusion, can help identify opportunities for improvement in the MT process.

The trauma center should review cases of massive transfusion with the following complications:

- Coagulopathy
- Thrombotic complications
- ARDS
- Other transfusion reactions, including TACO (transfusion-associated volume overload), TRALI (transfusion-related acute lung injury), and hemolytic transfusion reaction
- Over-transfusion of RBC
- Death



Performance indicators for the process of massive transfusion should include:

- Time from calling MTP to infusion of first unit RBC
- Time from calling MTP to infusion of first unit plasma
- Adherence to a predetermined ratio or goal between one to two hours after initiation of the MTP
- Informing the transfusion service that MTP has been terminated within one hour of termination
- Wastage rates for blood products



Bibliography

Introduction

Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations. *J Trauma*. 2006;60:53–511.

Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: A reassessment. *J Trauma*. 1995;38:185-193.

Spinella PC, Holcomb JB. Resuscitation and transfusion principles for traumatic hemorrhagic shock. *Blood Rev*. November 2009;23(6):231-240. Epub August 19, 2009. PMID:PMC3159517.

Hoyt DB, Bulger EM, Knudson MM, et al. Death in the operating room: An analysis of a multi-center experience. *J Trauma*. 1994;37:426-432.

Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. *Transfusion*. 2004;44:809-813.

Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: Comparative effectiveness of a time-varying treatment with competing risks. *JAMA Surg*. 2013;148(2):127-136.

Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: The impact of a trauma exsanguination protocol on survival and blood product utilization. *J Trauma*. 2008;64(5):1177-1182.

O'Keeffe T, Refaai M, Tchorz K, Forestner JE, Sarode R. A massive transfusion protocol to decrease blood component use and costs. *Arch Surg*. 2008;143(7):686-690.

Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. *J Trauma*. 2009;66(6):1616-1624.

Development of a Massive Transfusion Protocol: Engagement and Scope

Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: A reassessment. *J Trauma*. 1995;38:185-193

Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: The impact of a trauma exsanguination protocol on survival and blood product utilization. *J Trauma*. 2008;64(5):1177-1182

Riskin DJ, Tsai TC, Riskin L, et al. Massive transfusion protocols: The role of aggressive resuscitation versus product ratio in mortality reduction. *J Am Coll Surg*. 2009;209(2):198-205.

Triggers for Initiating Massive Transfusion

Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: The impact of a trauma exsanguination protocol on survival and blood product utilization. *J Trauma*. May 2008;64(5):1177-1182; discussion 1182-1173.

McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. *J Trauma*. February 2008;64(2 Suppl):S57-63; discussion S63.

Schreiber MA, Perkins J, Kiraly L, Underwood S, Wade C, Holcomb JB. Early predictors of massive transfusion in combat casualties. *J Am Coll Surg*. October 2007;205(4):541-545.

Yucel N, Lefering R, Maegele M, et al. Trauma Associated Severe Hemorrhage (TASH)-Score: Probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. *J Trauma*. June 2006;60(6):1228-1236; discussion 1236-1227.

Nunez TC, Voskresensky IV, Dossett LA, Shinall R, Dutton WD, Cotton BA. Early prediction of massive transfusion in trauma: Simple as ABC (assessment of blood consumption)? *J Trauma*. February 2009;66(2):346-352.

Cotton BA, Haut EH, Dossett LA, Shafi S, Au BK, Nunez TC, Johnston M, Arbogast P, Young PP. Multicenter validation of a simplified score to predict massive transfusion. *J Trauma*. 2010;69:S33-39.

Krumrei NJ, Park MS, Cotton BA, Zielinski MD. Comparison of massive blood transfusion predictive models in the rural setting. *J Trauma*. 2012;72:211-215.

Blood Product Resuscitation in the Trauma Bay, Operating Room, and Angiography Suite

Wehrli G, Taylor NE, Haines AL, Brady TW, Mintz PD. Instituting a thawed plasma procedure: It just makes sense and saves cents. *Transfusion*. 2009;49(12):2625-2630.

Radwan ZA, Bai Y, Matijevic N, del Junco DJ, McCarthy JJ, Wade CE, Holcomb JB, Cotton BA. An emergency department thawed plasma protocol for severely injured patients. *JAMA Surg*. 2013;148(2):170-175.



Zielinski MD, Johnson PM, Jenkins D, Goussous N, Stubbs JR. Emergency use of prethawed group A plasma in trauma patients. *J Trauma Acute Care Surg.* 2013;74:69-75.

Armand R, Hess JR. Treating coagulopathy in trauma patients. *Transfus Med Rev.* July 2003;17(3):223-231.

Massive Transfusion in the Intensive care Unit

Westbrook AJ, et al. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: A pilot study. *Heart Lung Circ.* 2009;18(4):277-288.

Royston D, von Kier S. Reduced hemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. *Br J Anaesth.* 2001;86(4):575-578.

Ark K, et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: A prospective randomized study. *J Card Surg.* 2009;24(4):404-410.

Operational Aspects of the Transfusion Service/Blood Bank

Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. *Transfusion.* June 2004;44(6):809-813.

Callum JL, Rizoli S. *ASH Education Book.* December 8, 2012;(1):522-528.

Dutton RP, Shih D, Edelman BB, Hess J, Scalea TM. Safety of uncrossmatched type-O red cells for resuscitation from hemorrhagic shock. *J Trauma.* December 2005;59(6):1445-1449.

Armand R, Hess JR. Treating coagulopathy in trauma patients. *Transfus Med Rev.* July 2003;17(3):223-231.

Quillen K, Sheldon SL, Daniel-Johnson JA, Lee-Stroka AH, Flegel WA. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. *Transfusion.* 2011;51(1):92-96.

Hess JR, Thomas MJ. Blood use in war and disaster: Lessons from the past century. *Transfusion.* November 2003;43(11):1622-1633.

Endpoints of Transfusion

Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR). Available at: <http://clinicaltrials.gov/show/NCT01545232>. Accessed March 28, 2013.

Holcomb JB, Minei KM, Scerbo ML, Radwan ZA, Wade CE, Kozar RA, Gill BS, Albarado R, McNutt MK, McCarthy JJ, Cotton BA. Admission rapid thrombelastography (r-TEG) can

replace conventional coagulation tests in the emergency department: Experience with 1974 consecutive trauma patients. *Ann Surg.* 2012;256(3):476-486.

Cotton BA, Cohen MJ, Camp E, Welch T, Redick B, Sticke R, Podbielski J, Holcomb JB, Schreiber MA. A multicenter study of rapid thrombelastography in predicting large volume transfusions. Presented at the 71st Annual Meeting of AAST and Clinical Congress of Acute Care Surgery, Kauai, HI; September 12-15, 2012.

Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon LH, Brasel KJ, Bulger EM, Cotton BA, Matijevic N, Muskat P, Myers JG, Phelan HA, White CE, Zhang J, Rahbar MH for the PROMMTT Study Group. The Prospective, Observational, Multicenter, Massive Transfusion study, PROMMTT: Comparative effectiveness of a time-varying treatment and competing risks. *JAMA Surg.* 2013;148(2):127-136.

Kashuk JL, Moore EE, Sawyer M, et al. Post injury coagulopathy management: goal directed resuscitation via POC thrombelastography. *Ann Surg.* 2010;251:604-614.

Pezold M, Moore EE, Wohlaer M, et al. Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes. *Surgery.* 2012;151:48-54.

Therapeutic Adjuncts in Massive Transfusion

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomized controlled trial. *Lancet.* 2011;377(9771):1096-1101, 1101.e1-2.

World Health Organization. WHO model lists of essential medicines. Available at: <http://www.who.int/medicines/publications/essentialmedicines/en/index.html>. Accessed April 30, 2013.

Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: Efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. *J Trauma.* 2010;69(3):489-500.

Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. *J Trauma.* 2007;62(3):564-569.

Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. *N Engl J Med.* 2010;363(19):1791-1800.

Antithrombotic Therapy and Prevention of Thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. February 2012;141(2_suppl).



Expert Panel

H. Gill Cryer, MD, FACS (Chair)

Professor of Surgery, Trauma/Emergency Surgery and Critical Care Program, UCLA, Los Angeles, CA

Avery B. Nathens, MD, FACS

Professor of Surgery, University of Toronto, Surgeon in Chief of Department of Surgery, Sunnybrook Hospital, Toronto, ON

Eileen M. Bulger, MD, FACS

Professor of Surgery and Chief of Trauma, University of Washington, Harborview Medical Center, Seattle, WA

J. Forrest Calland, MD, FACS

Assistant Professor of Surgery, University of Virginia Health System, Charlotte, VA

Mitchell J. Cohen, MD, FACS

Assistant Professor of Surgery, Division of General Surgery, University of California, San Francisco, CA

Bryan A. Cotton, MD, FACS, MPH

Associate Professor of Surgery, Division of Acute Care Surgery Department of Surgery, University of Texas, Houston, TX

Matthew L. Davis, MD, FACS

Assistant Professor of Surgery, Texas A&M COM, Trauma Program Director, Scott and White Healthcare System, Temple, TX

Mark R. Hemmila, MD, FACS

Associate Professor of Surgery, University of Michigan Health Systems, Ann Arbor, MI

John R. Hess, MD, MPH, FACP, FAAAS

Professor of Laboratory Medicine, University of Washington, Seattle, WA

Randeep Jawa, MD, FACS, FCCM

Visiting Associate Professor of Surgery, Division of Trauma, Emergency Surgery, and Surgical Critical Care, Stony Brook University School of Medicine, Stony Brook, NY

Rosemary Kozar, MD, FACS

Professor of Surgery and Chief of Trauma, Memorial Hermann Hospital, Houston, TX

Joseph Minei, MD, FACS

Professor of Surgery and Chief, Division of Burn, Trauma, and Critical Care, University of Texas Southwestern Medical Center, Dallas, TX

Katerina Pavenski, MD, FRCPC

Assistant Professor, Departments of Medicine and Laboratory Medicine and Pathology, University of Toronto, Toronto, ON

Martin Schreiber, MD, FACS

Professor of Surgery and Director of Trauma, Oregon Health & Science University, Portland, OR

Philip C. Spinella, MD, FCCM

Associate Professor of Pediatrics and Director, Critical Care Translational Research Program, Washington University, St. Louis, MO

Angela M. Ingraham, MD

Critical Care Medicine Fellow, University of Pittsburgh, PA

Hunter B. Moore, MD

Integrated Research Fellow, University of Colorado RAS Liason to ACS Committee on Trauma



The intent of the ACS TQIP Best Practices Guidelines is to provide health care professionals with evidence-based recommendations regarding care of the trauma patient. The Best Practices Guidelines do not include all potential options for prevention, diagnosis, and treatment and are not intended as a substitute for the provider's clinical judgment and experience. The responsible provider must make all treatment decisions based upon his or her independent judgment and the patient's individual clinical presentation. The ACS shall not be liable for any direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. The ACS may modify the TQIP Best Practices Guidelines at any time without notice.





AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

100years